U1162 – From Genomics to Therapeutic Targets
Collaborators: S Rebouissou (CR Inserm), Nahon (PUPH), AL Calatayud (PhD st), Jill Pilet (PhD st), S Schaeffer (AI), S Imbeaud (IR), S Caruso (Post-doctorant), JC Nault (MCUPH), J Zucman-Rossi (PUPH);
The molecular diversity and complexity of hepatocellular carcinoma (HCC), represent one of the major barriers precluding the development of effective therapeutic strategies thereby there is an urgent need to find biomarkers that can help at identifying subsets of HCC patients that are more likely to respond to a given treatment. For this purpose we develop two main projects :
1) Drug screening in liver cancer cell lines molecularly characterized: our first purpose is to search for correlations between pharmacological responses to candidate drugs and molecular profiles across a large panel of 34 liver cancer cell lines characterized extensively at the genomic and protein level and reflecting the molecular diversity of primary tumors seen in the clinic, in order to identify new potential attractive drugs in the treatment of HCC and molecular markers predicting their sensitivity.
2) Genomic analysis of tumor samples from patients included in clinical trials: our second aim is to collect tumor samples from HCC patients included in clinical trials in order to link tumor molecular alterations and microenvironment to the clinical therapeutic response. Ex: Nivolep Trial: “Immunotherapy in neoadjuvant and adjuvant setting in patients with advanced HCC treated by electroporation in curative intent: French multicenter phase 2 therapeutic trial coordinated by P Nahon.
Dual targeting of histone methyltransferase G9a and DNA-methyltransferase 1 for the treatment of experimental hepatocellular carcinoma.
Related ArticlesDual targeting of histone methyltransferase G9a and DNA-methyltransferase 1 for the treatment of experimental hepatocellular […]